Takeda Pharmaceutical Company Limited Logo

Takeda Pharmaceutical Company Limited

R&D-driven biopharma creating medicines for Oncology, Rare Diseases, GI, and Neuroscience.

4502 | T

Overview

Corporate Details

ISIN(s):
JP3463000004
LEI:
Country:
Japan
Address:
大阪市中央区道修町四丁目1番1号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Takeda Pharmaceutical Company Limited is a global, R&D-driven biopharmaceutical leader dedicated to discovering and delivering life-transforming treatments. With a history spanning over 240 years, the company translates science into highly innovative medicines. Its core business activities include the research, development, manufacturing, and commercialization of pharmaceutical drugs. Takeda focuses its efforts on four core therapeutic areas: Oncology, Rare Diseases, Gastroenterology, and Neuroscience, with additional targeted investments in Plasma-Derived Therapies and Vaccines. The company is committed to a patient-centered approach, aiming to create better health and a brighter future for people worldwide through its diverse and balanced portfolio.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-30 07:48
Interim Report
確認書
Japanese 9.4 KB
2025-10-30 07:47
Interim Report
半期報告書-第149期(2025/04/01-2026/03/31)
Japanese 483.8 KB
2025-10-30 07:43
Earnings Release
Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consol…
English 22.5 KB
2025-07-01 05:11
Registration Form
訂正発行登録書
Japanese 11.9 KB
2025-07-01 05:11
Registration Form
訂正発行登録書
Japanese 11.3 KB
2025-07-01 05:11
Post-Annual General Meeting Information
臨時報告書
Japanese 28.6 KB
2025-06-25 09:33
Registration Form
確認書
Japanese 9.4 KB
2025-06-25 09:32
Governance Information
内部統制報告書-第148期(2024/04/01-2025/03/31)
Japanese 26.8 KB
2025-06-25 09:31
Annual Report
有価証券報告書-第148期(2024/04/01-2025/03/31)
Japanese 3.6 MB
2025-06-12 04:51
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 25.0 KB
2025-06-10 08:31
Registration Form
発行登録追補書類(株券、社債券等)
Japanese 65.6 KB
2025-06-06 03:43
Registration Form
発行登録追補書類(株券、社債券等)
Japanese 129.2 KB
2025-06-02 08:34
Registration Form
発行登録書(株券、社債券等)
Japanese 50.3 KB
2025-05-14 05:06
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 31.7 KB
2025-04-14 04:57
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 26.5 KB

Automate Your Workflow. Get a real-time feed of all Takeda Pharmaceutical Company Limited filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Takeda Pharmaceutical Company Limited

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Takeda Pharmaceutical Company Limited via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
BRISTOL MYERS SQUIBB CO Logo
Develops innovative medicines for oncology, immunology, and cardiovascular diseases.
United States of America BMY
R&D pharma firm developing drugs for CNS disorders, oncology, and metabolic diseases.
South Korea 003000
Burning Rock Biotech Ltd Logo
Offers NGS-based diagnostics for precision oncology, from detection to clinical trial support.
United States of America BNR
C4 Therapeutics, Inc. Logo
Developing protein degrader medicines to treat cancer and other serious diseases.
United States of America CCCC
Cabaletta Bio, Inc. Logo
Develops engineered T cell therapies for a curative reset in autoimmune diseases.
United States of America CABA
Cadrenal Therapeutics, Inc. Logo
Developing novel anticoagulant therapies for high-risk cardiovascular patients.
United States of America CVKD
CalciMedica, Inc. Logo
Develops CRAC channel inhibitors for critical illnesses like acute pancreatitis & AKI.
United States of America CALC
Calidi Biotherapeutics, Inc. Logo
Develops immunotherapies using stem cells to deliver oncolytic viruses against solid tumors.
United States of America CLDI
Calliditas Therapeutics Logo
Develops and commercializes novel treatments for rare renal and hepatic diseases like IgA nephropathy.
Sweden CALTX
CALTH. Inc Logo
Develops AI-powered rapid diagnostic solutions for point-of-care and self-testing.
South Korea 402420

Talk to a Data Expert

Have a question? We'll get back to you promptly.